StockTipsArenaBeta

BUY RPG Life Sciences Limited — ICICI Securities

BUYRPG Life Sciences Limited

byICICI SecuritiesHorizon: NA (inferred 1 year)4 Sept 2026via Institutional / Brokerage Research

Entry₹2,721.6Inferred
Target₹3,205
Total upside +17.76%
Stop lossNot given
CMP₹2,721.62d ago
Active0.00%+17.76%upside left 12 mo left
Follow ICICI Securities for new calls(67% target hit, 1029 closed calls)Get alertsWatch RPGLIFE for new buy/sell callsGet alertsSee 1 other Long-term call on RPGLIFESee 196 other Long-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 6 Sept, 7:40 pm IST
8 supporting3 neutral0 opposing
Supports the BUY call (8)

Long-term trend bullish — 200-day average rising over the past quarter

Technicals · trend·4 Sept · 2d ago

RPG Life Sciences' subsidiary, RPG Active Pharma, is acquiring the API business of Raghava Life Sciences for up to 135 crore. This acquisition includes a manufacturing facility and a portfolio of 22 c

BSE · Company Update·2 Sept · 3d ago

(opens in new tab)

RPG Life Sciences' wholly owned subsidiary, RPG Active Pharma Limited, will acquire the API and intermediates business of Raghava Life Sciences Private Limited via slump sale for up to Rs. 135 crores.

BSE · Company Update·2 Sept · 3d ago

(opens in new tab)

1 other SEBI-registered advisor has an active long-term BUY call on this stock

Advisor consensus · same horizon·20 Aug · 2w ago

Neutral / worth noting (3)

RPG Life Sciences Ltd has completed transactions related to the API Business Transfer Agreement with RPG Active Pharma Limited.

BSE · Company Update·15 Aug · 3w ago

(opens in new tab)
Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

StockTipsArena© 2026 · NSE equities only · Not investment advicePublic beta · data is auto-aggregated from public sources and may contain errors — verify before acting.